CARL HOWARD JUNE
Medical Practice in Merion Station, PA
License number
Pennsylvania MD070637L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Merion Station, PA 19066
Personal information
See more information about CARL HOWARD JUNE at radaris.comName
Address
Phone
120 Howard St, Kingston, PA 18704
137 Wilson St, Kingston, PA 18704
3033 S Main St, Hanover Township, PA 18706
409 Baird Rd, Merion Sta, PA 19066
409 Baird Rd, Merion Sta, PA 19066
Professional information
Methods Of Generating Human Cd4+ Th1 Cells
US Patent:
2004024, Dec 2, 2004
Filed:
Feb 27, 2004
Appl. No.:
10/488196
Inventors:
Daniel Fowler - Bethesda MD, US
Jeanne Hou - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Ronald Gress - Gaithersburg MD, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US
Jeanne Hou - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Ronald Gress - Gaithersburg MD, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US
International Classification:
A61K045/00, C12N005/08
US Classification:
424/093710, 435/372000
Abstract:
Methods are provided for producing a population of substantially purified CD4+ Th1 lymphocytes. The method includes stimulating a population of substantially purified CD4+ T cells isolated from a subject by contacting the population with an anti-CD3 monoclonal antibody and an antibody that specifically binds to a T cell costimulatory molecule in the presence of a Th1 supportive environment to form a stimulated population of T cells. The stimulated population of CD4+ T cells is allowed to proliferate in a Th1 supportive environment. In one example, the Th1 supportive environment includes at least 20 IU/ml of IL-2, for example about 1000 I.U./ml of IL-2, and a neutralizing amount of an IL-4, an IL-13, and/or an IL-4/IL-13 neutralizing agent. In other examples, the supportive environment further includes at least 1 ng/ml of IL-12, for example about 2.5 ng/ml of IL-12. Purified populations of Th1 cells are disclosed herein, as are methods for their use.
Activation And Expansion Of T-Cells Using An Engineered Multivalent Signaling Platform As A Research Tool
US Patent:
8637307, Jan 28, 2014
Filed:
May 10, 2010
Appl. No.:
12/777053
Inventors:
Carl H. June - Merion Station PA, US
James L. Riley - Downingtown PA, US
Marcela Maus - Wynnewood PA, US
Anna Thomas - Freiburg, DE
Robert Vonderheide - Merion Station PA, US
James L. Riley - Downingtown PA, US
Marcela Maus - Wynnewood PA, US
Anna Thomas - Freiburg, DE
Robert Vonderheide - Merion Station PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12N 5/02, C12N 5/06, C12N 5/08, C12N 5/00, C07K 16/00
US Classification:
435325, 435326, 435355, 435372, 4353728
Abstract:
Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.
Regulatory T Cells And Their Use In Immunotherapy And Suppression Of Autoimmune Responses
US Patent:
7651855, Jan 26, 2010
Filed:
Apr 19, 2004
Appl. No.:
10/827023
Inventors:
Bruce Blazar - Golden Valley MN, US
Carl June - Merion Station PA, US
Wayne R. Godfrey - Birchwood MN, US
Richard G. Carroll - Lansdowne PA, US
Bruce Levine - Cherry Hill NJ, US
James L. Riley - Downingtown PA, US
Patricia Taylor - St. Paul MN, US
Carl June - Merion Station PA, US
Wayne R. Godfrey - Birchwood MN, US
Richard G. Carroll - Lansdowne PA, US
Bruce Levine - Cherry Hill NJ, US
James L. Riley - Downingtown PA, US
Patricia Taylor - St. Paul MN, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12N 5/00
US Classification:
435375, 435373
Abstract:
Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4CD25 suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.
Methods For Treating Hiv Infected Subjects
US Patent:
2009015, Jun 18, 2009
Filed:
Oct 22, 2008
Appl. No.:
12/255861
Inventors:
Carl H. JUNE - Merion Station PA, US
Craig B. THOMPSON - Merion PA, US
Gary J. NABEL - Washington DC, US
Gary S. GRAY - Brookline MA, US
Paul D. RENNERT - Holliston MA, US
Craig B. THOMPSON - Merion PA, US
Gary J. NABEL - Washington DC, US
Gary S. GRAY - Brookline MA, US
Paul D. RENNERT - Holliston MA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
GENETICS INSTITUTE, LLC - Cambridge MA
The United States of America as Represented by the Secretary of the Navy - Arlington VA
GENETICS INSTITUTE, LLC - Cambridge MA
The United States of America as Represented by the Secretary of the Navy - Arlington VA
International Classification:
C12Q 1/02, C12N 5/02
US Classification:
435 29, 435375
Abstract:
Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
Regulatory T Cells And Their Use In Immunotherapy And Suppression Of Autoimmune Responses
US Patent:
8129185, Mar 6, 2012
Filed:
Dec 29, 2009
Appl. No.:
12/649101
Inventors:
Bruce Blazar - Golden Valley MN, US
Carl June - Merion Station PA, US
Wayne R. Godfrey - Los Altos CA, US
Richard G. Carroll - Lansdowne PA, US
Bruce Levine - Cherry Hill NJ, US
James L. Riley - Downingtown PA, US
Patricia Taylor - St. Paul MN, US
Carl June - Merion Station PA, US
Wayne R. Godfrey - Los Altos CA, US
Richard G. Carroll - Lansdowne PA, US
Bruce Levine - Cherry Hill NJ, US
James L. Riley - Downingtown PA, US
Patricia Taylor - St. Paul MN, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12N 5/071, C12N 5/00, A01N 63/00
US Classification:
4353723, 435325, 435363, 435366, 424 931, 424 932
Abstract:
Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4CD25 suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.
Use Of Chimeric Antigen Receptor-Modified T-Cells To Treat Cancer
US Patent:
2013028, Oct 31, 2013
Filed:
Dec 9, 2011
Appl. No.:
13/992622
Inventors:
Carl H. June - Merion Station PA, US
Bruce L. Levine - Cherry Hill NJ, US
David L. Porter - Springfield PA, US
Michael D. Kalos - Philadelphia PA, US
Michael C. Milone - Cherry Hill NJ, US
Bruce L. Levine - Cherry Hill NJ, US
David L. Porter - Springfield PA, US
Michael D. Kalos - Philadelphia PA, US
Michael C. Milone - Cherry Hill NJ, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 35/14
US Classification:
424 9321, 536 234, 5303873, 435328, 4353201
Abstract:
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
Methods For Treating Progressive Multifocal Leukoencephalopathy (Pml)
US Patent:
8415150, Apr 9, 2013
Filed:
Feb 24, 2010
Appl. No.:
13/201829
Inventors:
Carl H. June - Merion Station PA, US
Bruce Levine - Cherry Hill NJ, US
Anne Chew - Cherry Hill NJ, US
Stephen J. Schuster - Springfield PA, US
Bruce Levine - Cherry Hill NJ, US
Anne Chew - Cherry Hill NJ, US
Stephen J. Schuster - Springfield PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12N 5/00
US Classification:
435325
Abstract:
The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
Methods To Expand A T Regulatory Cell Master Cell Bank
US Patent:
2013010, Apr 25, 2013
Filed:
Mar 28, 2011
Appl. No.:
13/639927
Inventors:
James L. Riley - Downingtown PA, US
Carl H. June - Merion Station PA, US
Bruce R. Blazar - Golden Valley MN, US
Keli Hippen - Robbinsdale MN, US
Carl H. June - Merion Station PA, US
Bruce R. Blazar - Golden Valley MN, US
Keli Hippen - Robbinsdale MN, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12N 5/0783
US Classification:
424 9371, 435325, 435375
Abstract:
Compositions and methods for expanding natural T regulatory cells (nTregs) without substantially sacrificing suppressive function of the cells are disclosed. Also provided are uses of the expanded nTregs for cellular therapy.
Activation And Expansion Of T-Cells Using An Engineered Multivalent Signaling Platform
US Patent:
7638325, Dec 29, 2009
Filed:
Jan 3, 2003
Appl. No.:
10/336224
Inventors:
Carl June - Merion Station PA, US
James Riley - Downingtown PA, US
Marcela Maus - Wynnewood PA, US
Anna Thomas - Bergisch Gladbach, DE
James Riley - Downingtown PA, US
Marcela Maus - Wynnewood PA, US
Anna Thomas - Bergisch Gladbach, DE
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12N 5/02, C12N 5/06, C12N 15/00, C12N 15/63, C07K 16/00
US Classification:
435325, 435326, 435440, 435455
Abstract:
The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells using an engineered multivalent signaling platform. Compositions of cells activated and expanded by the methods herein are further provided.
Modulation Of Regulatory T Cells By Human Il-18
US Patent:
2010006, Mar 11, 2010
Filed:
Sep 14, 2007
Appl. No.:
12/441051
Inventors:
Richard G. Carroll - Landsdowne PA, US
Xiaochuan Shan - Cherry Hill NJ, US
Carl H. June - Merion Station PA, US
Xiaochuan Shan - Cherry Hill NJ, US
Carl H. June - Merion Station PA, US
International Classification:
A61K 38/20, A61P 35/00
US Classification:
424 852
Abstract:
The present invention relates to compositions and methods for modulating the presence and/or activity of regulatory T cells in a subject.